AmolMehtaMD Profile Banner
Amol Mehta, MD Profile
Amol Mehta, MD

@AmolMehtaMD

Followers
344
Following
1K
Media
14
Statuses
244

Neuroendovascular Surgery Fellow @MountSinai former @Columbianeuron Interested in: Neurointervention, Stroke, Public Health, Jazz Saxophone

Joined September 2012
Don't wanna be here? Send us removal request.
@MountSinaiNeuro
Mount Sinai Neurosurgery
3 days
The 36th Sidney A Hollin, MD, Memorial Lecture was a success! #HollinLecture guest speaker Dr @jmascite (@UTHealthSA + @MountSinaiNeuro residency & #NeuroendovascularSurgery fellow alum) presented “Open #VascularNeurosurgery Is Not Dead Yet!” Thanks for sharing your expertise!🧠
2
4
15
@Fie0815
Jens Fiehler
9 days
Positive 12M results in bailout PTA/Stenting in 🇨🇳REBOOT RCT. https://t.co/buTxIggXWS PTA/Stenting improved 1-year mRS (gOR, 1.34). Fewer stroke recurrences (4% vs. 13%). @_AdnanSiddiqui @Acandisgmbh @STateshimaMD @Cure4Stroke
4
18
39
@ShadiYaghi2
Shadi Yaghi
16 days
Early recurrence in medically treated patients with symptomatic ICAS is driven by impaired distal perfusion. Happy to share that the BIORISK ICAS study was presented at WSC and published in stroke. I am grateful for our collaborators from across the world. https://t.co/wAnHhGvUPp
2
32
90
@NeuroIRdoc
Amit Chaudhari MD
1 month
Dr. Rahmani and others supporting endovascular venous thrombectomy. Rare cause of stroke, but with new devices, intervention may be the best option https://t.co/0Y449hcjLP
jnis.bmj.com
Cerebral venous sinus thrombosis (CVST) is a relatively rare type of stroke (0.5% of all strokes), with a prevalence of 5 per million people.1 It predominantly affects younger age groups, particula...
0
3
10
@JAMANeuro
JAMA Neurology
1 month
Editorial: The ATIS-NVAF trial shows adding antiplatelet therapy to OAC in stroke patients with AF and atherosclerotic disease increases major bleeding without significant reduction in ischemic events. https://t.co/4qDFaL6m5H
0
44
132
@AmolMehtaMD
Amol Mehta, MD
1 month
Yes. I’d change my practice based on this even though it’s a subgroup analysis
@StrokeAHA_ASA
Stroke AHA/ASA
1 month
#STROKE: In a secondary analysis of ARCADIA, randomization to apixaban was associated with a lower risk of recurrent ischemic stroke than aspirin in patients with left ventricular systolic dysfunction. @MitchElkind @hoomankamel @ShadiYaghi2 #AHAJournals https://t.co/3fntF9AlNV
0
0
2
@stephanamayer
Stephan A Mayer
2 months
Thrombectomy is superior to Best Medical Therapy for LVO stroke w/ penumbra presenting Beyond 24 Hours: A Systematic Review and Meta-Analysis https://t.co/y6lXcIwky1
Tweet card summary image
ahajournals.org
BACKGROUND: The benefit of endovascular thrombectomy (EVT) beyond 24 hours from last known well in acute ischemic stroke remains uncertain. Although some slow progressors may retain salvageable...
1
28
60
@NN_publishing
NeuroNews
2 months
EVT is a technically feasible approach that may also produce positive clinical outcomes in the treatment of symptomatic intradural CTOs, according to Re-CHILL study findings disclosed at the 2025 @esmintsociety congress by @PCimflova https://t.co/pnRrIXvwRs
Tweet card summary image
neuronewsinternational.com
Endovascular therapy (EVT) appears to be a technically feasible approach that may also produce positive clinical outcomes in the treatment of symptomatic intradural chronic total occlusions (CTOs),...
0
1
6
@GravityMedTech
Gravity Medical Technology
2 months
We are excited to announce that the primary results of the pioneering GRASSROOT INDIA Trial will be presented for the first time at the World Stroke Congress 2025 in Barcelona, Spain on October 23rd #GRASSROOT #GravityMedTech #Supernova #IndiaApproval #WSC2025 #onecountryatatime
0
5
16
@StrokeAHA_ASA
Stroke AHA/ASA
2 months
#STROKE: This special report by @AmolMehtaMD et al. critically appraises recent literature on endovascular thrombectomy for medium vessel occlusion stroke and offers consideration for practice. #AHAJournals https://t.co/BKDnRMukbo
3
42
162
@StrokeAHA_ASA
Stroke AHA/ASA
2 months
#STROKE: In a case series of patients with acute stroke, photon-counting CT was able to accurately distinguish contrast extravasation from intracranial hemorrhage. #AHAJournals https://t.co/T9lcNBEHnu
0
19
67
@AshuPJadhav
AshuJadhav
2 months
Consensus Statement on Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Treatment https://t.co/PmmAomxaXR @StrokeAHA_ASA @SVINJournal @StrokeAHA_ASA
1
33
106
@JAMANeuro
JAMA Neurology
2 months
In anterior circulation stroke patients post-thrombectomy, low and medium doses of intra-arterial tenecteplase demonstrated adequate safety to warrant larger trials to investigate their therapeutic potential. https://t.co/yWAe7yPCSN
0
27
62
@AmolMehtaMD
Amol Mehta, MD
2 months
The GRASSROOT India Trial results will be presented for the 1st time at the WSC 2025 in Barcelona. This landmark study served as the foundation for the approval of the Supernova stent retriever in India-a pivotal step in our mission to expand access to high-quality stroke care.
1
1
4
@JAMANeuro
JAMA Neurology
2 months
Aneurysm wall enhancement on MRI, particularly circumferential AWE, may be used to predict the risk of instability in unruptured intracranial aneurysms over a four-year period. https://t.co/3QiuYDbYEa
0
26
79
@stephanamayer
Stephan A Mayer
2 months
Did you know that thrombectomy NEVER WORKED until suddenly it did in Oct 2015? 😜 Of course it did. It’s all about pt selection. I agree with these guys re: MeVO. Should We Stop Endovascular Treatment of M2 Occlusions?: A Critical Look
Tweet card summary image
ahajournals.org
Medium vessel occlusions represent a substantial proportion of patients with acute ischemic stroke. Recently presented randomized controlled trials, ESCAPE-MeVO (Endovascular Treatment to Improve...
2
16
56
@AmolMehtaMD
Amol Mehta, MD
3 months
Thrilled to publish this piece in @StrokeAHA_ASA alongside several of my mentors to hopefully clarify current dilemmas on the treatment of M2 occlusions, and to encourage the community to treat proximal/dominant M2s in the post MEVO trial era.
@Daryl_Goldman
Daryl Goldman MD
3 months
Proximal and/or dominant M2=TREAT‼️Jury out on other M2’s but likely treat if disabling! Check out more here!⁦ @AmolMehtaMD⁩ ⁦@JMoccoMD⁩ ⁦@eytanraz⁩ ⁦@ShashvatDesai⁩ ⁦@NguyenThanhMD⁩ ⁦@SunilAShethMD⁩ ⁦@AshuPJadhav
1
22
80
@AmolMehtaMD
Amol Mehta, MD
3 months
Being a senior fellow is sweett. TICI3 1 pass, 7 min groin puncture to recanalization! With Zoom 7X and CDAT! @ImpCare_Vasc under the auspices of @MajidiShahram NIHSS 7->1 and no infarct on MRI
0
1
7